CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Novo Nordisk A/S

NVO
$253.81B
Mega Cap
NYSEBiotechnology🇩🇰Europe78.6K employees
Website

Drugs in Pipeline

101

Phase 3 Programs

76

Upcoming Catalysts

19

Next Catalyst

Feb 20, 2026

12d
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

19 upcoming, 0 past

⭐Phase 3Next

Semaglutide Phase 3 Results Expected

Feb 20, 2026Semaglutide1,000

Primary completion for Semaglutide trial (NCT06221969) in Type 2 Diabetes

Source
⭐Phase 3

Cagrilintide Phase 3 Results Expected

Feb 20, 2026Cagrilintide1,000

Primary completion for Cagrilintide trial (NCT06221969) in Type 2 Diabetes

Source
⭐Phase 3

Tirzepatide Phase 3 Results Expected

Feb 20, 2026Tirzepatide1,000

Primary completion for Tirzepatide trial (NCT06221969) in Type 2 Diabetes

Source
⭐Phase 3

Cagrilintide Phase 3 Results Expected

Apr 21, 2026Cagrilintide300

Primary completion for Cagrilintide trial (NCT06388187) in Obesity

Source
⭐Phase 3

Semaglutide Phase 3 Results Expected

Apr 21, 2026Semaglutide300

Primary completion for Semaglutide trial (NCT06388187) in Obesity

Source
⭐Phase 3

Concizumab Phase 3 Results Expected

Apr 21, 2026Concizumab153

Primary completion for Concizumab trial (NCT05135559) in Haemophilia A and B With and Without Inhibitors

Source
⭐Phase 3

Semaglutide Phase 3 Results Expected

Jun 2, 2026Semaglutide1,023

Primary completion for Semaglutide trial (NCT06534411) in Diabetes Mellitus, Type 2

Source
⭐Phase 3

Tirzepatide Phase 3 Results Expected

Jun 2, 2026Tirzepatide1,023

Primary completion for Tirzepatide trial (NCT06534411) in Diabetes Mellitus, Type 2

Source
⭐Phase 3

Cagrilintide Phase 3 Results Expected

Jun 2, 2026Cagrilintide1,023

Primary completion for Cagrilintide trial (NCT06534411) in Diabetes Mellitus, Type 2

Source
⭐Phase 3

Oral semaglutide Phase 3 Results Expected

Aug 21, 2026Oral semaglutide264

Primary completion for Oral semaglutide trial (NCT07271251) in Type 2 Diabetes

Source
Phase 2

NNC0519-0130 Phase 2 Results Expected

Sep 1, 2026NNC0519-0130465

Primary completion for NNC0519-0130 trial (NCT06717698) in Chronic Kidney Disease

Source
Phase 2

Semaglutide Phase 2 Results Expected

Sep 1, 2026Semaglutide465

Primary completion for Semaglutide trial (NCT06717698) in Chronic Kidney Disease

Source
⭐Phase 3

Ziltivekimab Phase 3 Results Expected

Sep 3, 2026Ziltivekimab10,000

Primary completion for Ziltivekimab trial (NCT06118281) in Cardiovascular Risk

Source
⭐Phase 3

Ziltivekimab Phase 3 Results Expected

Oct 5, 2026Ziltivekimab680

Primary completion for Ziltivekimab trial (NCT06200207) in Heart Failure

Source
⭐Phase 3

Insulin glargine Phase 3 Results Expected

Nov 23, 2026insulin glargine877

Primary completion for Insulin glargine trial (NCT07076199) in Diabetes Mellitus, Type 1

Source
⭐Phase 3

Insulin aspart Phase 3 Results Expected

Nov 23, 2026insulin aspart877

Primary completion for Insulin aspart trial (NCT07076199) in Diabetes Mellitus, Type 1

Source
⭐Phase 3

Insulin icodec Phase 3 Results Expected

Nov 23, 2026Insulin Icodec877

Primary completion for Insulin icodec trial (NCT07076199) in Diabetes Mellitus, Type 1

Source
Phase 2

NNC0662-0419 Phase 2 Results Expected

Dec 1, 2026NNC0662-0419220

Primary completion for NNC0662-0419 trial (NCT07184632) in Overweight

Source
⭐Phase 3

Semaglutide Phase 3 Results Expected

Dec 25, 2026Semaglutide1,500

Primary completion for Semaglutide trial (NCT03811561) in Diabetes Mellitus, Type 2

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

inhaled human insulin

Phase 3

Diabetes

Semaglutide 1.0 mg

Phase 3

Obesity

turoctocog alfa pegol (N8-GP)

Phase 3

Haemophilia A

DCR-PHXC

Phase 3

Primary Hyperoxaluria Type 1 (PH1)

exenatide

Phase 3

Diabetes

repaglinide and metformin combination tablet

Phase 3

Diabetes

Insulin glargine U100

Phase 3

Diabetes Mellitus, Type 2

repaglinide

Phase 3

Diabetes

biphasic human insulin 50

Phase 3

Diabetes

insulin human

Phase 3

Diabetes

NNC6019-0001

Phase 3

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Etavopivat

Phase 3

Sickle Cell Disease

semaglutide 50 mg

Phase 3

Overweight and Obesity

CagriSema (Cagrilintide B and Semaglutide I)

Phase 3

Obesity

Canagliflozin

Phase 3

Diabetes

sulfonylurea

Phase 3

Diabetes

vatreptacog alfa (activated)

Phase 3

Congenital Bleeding Disorder

empagliflozin

Phase 3

Diabetes

Norditropin

Phase 3

Growth Hormone Disorder

biphasic insulin aspart 70

Phase 3

Diabetes

estradiol, 25 mcg

Phase 3

Menopause

insulin

Phase 3

Diabetes

17-beta estradiol

Phase 3

Genetic Disorder

estradiol, 10 mcg

Phase 3

Menopause

Semagludtide

Phase 3

Early Alzheimer's Disease

glibenclamide

Phase 3

Diabetes

eptacog alfa (activated)

Phase 3

Acquired Bleeding Disorder

biphasic insulin aspart

Phase 3

Diabetes

Cagrilintide

Phase 3

Obesity or Overweight

Concizumab

Phase 3

Congenital Bleeding Disorder

sitagliptin

Phase 3

Diabetes

biphasic human insulin

Phase 3

Diabetes

Insulin Icodec

Phase 3

Diabetes Mellitus, Type 2

human insulin

Phase 3

Diabetes

insulin NPH

Phase 3

Diabetes

metformin

Phase 3

Diabetes

turoctocog alfa pegol

Phase 3

Congenital Bleeding Disorder

rosiglitazone

Phase 3

Diabetes

biphasic insulin aspart 50

Phase 3

Diabetes

DPP-4 inhibitor

Phase 3

Diabetes

NNC0365-3769 (Mim8)

Phase 3

Haemophilia A

Insulin Glargine 100U/mL

Phase 3

Diabetes Mellitus, Type 2

Norditropin®

Phase 3

Growth Hormone Deficiency in Children

nonacog beta pegol

Phase 3

Congenital Bleeding Disorder

glimepiride

Phase 3

Diabetes

NPH insulin

Phase 3

Diabetes

Turoctocog alfa

Phase 3

Haemostasis

Insuline glargine U100 (reduced)

Phase 3

Diabetes Mellitus, Type 2

Ziltivekimab

Phase 3

Heart Failure

pioglitazone

Phase 3

Diabetes

Oral semaglutide

Phase 3

Diabetes Mellitus, Type 2

Faster-acting insulin aspart

Phase 3

Diabetes

Semaglutide 0.5 mg

Phase 3

Diabetes

somapacitan

Phase 3

Adult Growth Hormone Deficiency

human soluble insulin

Phase 3

Diabetes

oral anti-diabetic drug

Phase 3

Diabetes

Mim8

Phase 3

Haemophilia A

IcoSema

Phase 3

Type 2 Diabetes

insulin detemir

Phase 3

Diabetes

Semaglutide 2.4 mg

Phase 3

Obesity

Dulaglutide

Phase 3

Diabetes

somatropin

Phase 3

Growth Hormone Disorder

biphasic insulin aspart 30

Phase 3

Diabetes

activated recombinant human factor VII

Phase 3

Acquired Bleeding Disorder

Semaglutide

Phase 3

Obesity

insulin aspart

Phase 3

Diabetes

insulin degludec/liraglutide

Phase 3

Diabetes

insulin degludec

Phase 3

Diabetes

catridecacog

Phase 3

Congenital Bleeding Disorder

liraglutide

Phase 3

Diabetes

insulin degludec/insulin aspart

Phase 3

Diabetes

insulin glargine

Phase 3

Diabetes

Tirzepatide

Phase 3

Diabetes Mellitus, Type 2

Semaglutide 1 mg

Phase 3

Diabetes Mellitus, Type 2

insulin lispro

Phase 3

Diabetes

Semaglutide J

Phase 3

Diabetes Mellitus, Type 2

CDR132L

Phase 2

Heart Failure

NNC0194 0499 50 mg/mL

Phase 2

Non-alcoholic Steatohepatitis

NNC109-0012

Phase 2

Inflammation

NNC 0151-0000-0000

Phase 2

Inflammation

Norditropin® FlexPro® pen

Phase 2

Growth Hormone Disorder

NDec - oral decitabine-tetrahydrouridine

Phase 2

Sickle Cell Disease

Cagrilintide 2.4 mg

Phase 2

Diabetes Mellitus, Type 2

Fast-acting insulin aspart

Phase 2

Diabetes Mellitus, Type 1

NNC0174-0833

Phase 2

Overweight

insulin 338 (GIPET I)

Phase 2

Diabetes

NNC0114-0006

Phase 2

Diabetes

Semaglutide 2.4 mg and NNC0165-1875 2.0 mg

Phase 2

Obesity

NNC0662-0419

Phase 2

Overweight

NNC0194-0499

Phase 2

Alcohol-related Liver Disease

biphasic human insulin 30

Phase 2

Diabetes

nedosiran

Phase 2

Primary Hyperoxaluria

NNC0487-0111 subcutanous

Phase 2

Type 2 Diabetes (T2D)

Semaglutide (administered by DV3396 pen)

Phase 2

Healthy Volunteers Diabetes Mellitus, Type 2

sunitinib

Phase 2

Cancer

NNC126-0083

Phase 2

Growth Hormone Disorder

NNC0090-2746

Phase 2

Diabetes

EX1000

Phase 2

Diabetes

NNC0487-0111

Phase 2

Obesity

recombinant interleukin-21

Phase 2

Cancer

NNC0519-0130

Phase 2

Diabetes Mellitus, Type 2

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals
NVO News